AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
ASTRAZENECA PHARMA | SUN PHARMA | ASTRAZENECA PHARMA/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 145.2 | 135.0 | 107.6% | View Chart |
P/BV | x | 40.8 | 3.1 | 1,318.7% | View Chart |
Dividend Yield | % | 0.0 | 0.7 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
SUN PHARMA Mar-20 |
ASTRAZENECA PHARMA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 484 | 264.0% | |
Low | Rs | 883 | 315 | 280.0% | |
Sales per share (Unadj.) | Rs | 228.4 | 136.9 | 166.9% | |
Earnings per share (Unadj.) | Rs | 10.4 | 17.5 | 59.4% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 26.0 | 62.5% | |
Dividends per share (Unadj.) | Rs | 0 | 4.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.0 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 188.7 | 52.4% | |
Shares outstanding (eoy) | m | 25.00 | 2,399.26 | 1.0% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 2.9 | 162.0% | |
Avg P/E ratio | x | 104.2 | 22.9 | 455.1% | |
P/CF ratio (eoy) | x | 66.4 | 15.4 | 432.3% | |
Price / Book Value ratio | x | 10.9 | 2.1 | 516.3% | |
Dividend payout | % | 0 | 22.9 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 958,864 | 2.8% | |
No. of employees | `000 | 1.4 | 17.8 | 7.6% | |
Total wages/salary | Rs m | 1,535 | 63,624 | 2.4% | |
Avg. sales/employee | Rs Th | 4,210.9 | 18,490.6 | 22.8% | |
Avg. wages/employee | Rs Th | 1,132.2 | 3,582.6 | 31.6% | |
Avg. net profit/employee | Rs Th | 191.1 | 2,357.6 | 8.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 328,375 | 1.7% | |
Other income | Rs m | 123 | 6,360 | 1.9% | |
Total revenues | Rs m | 5,833 | 334,735 | 1.7% | |
Gross profit | Rs m | 463 | 69,898 | 0.7% | |
Depreciation | Rs m | 147 | 20,528 | 0.7% | |
Interest | Rs m | 0 | 3,027 | 0.0% | |
Profit before tax | Rs m | 438 | 52,702 | 0.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,606 | 0.0% | |
Tax | Rs m | 179 | 8,228 | 2.2% | |
Profit after tax | Rs m | 259 | 41,868 | 0.6% | |
Gross profit margin | % | 8.1 | 21.3 | 38.1% | |
Effective tax rate | % | 40.8 | 15.6 | 261.6% | |
Net profit margin | % | 4.5 | 12.8 | 35.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 316,542 | 1.0% | |
Current liabilities | Rs m | 2,070 | 157,064 | 1.3% | |
Net working cap to sales | % | 20.0 | 48.6 | 41.1% | |
Current ratio | x | 1.6 | 2.0 | 76.9% | |
Inventory Days | Days | 72 | 88 | 82.6% | |
Debtors Days | Days | 35 | 105 | 33.3% | |
Net fixed assets | Rs m | 790 | 243,102 | 0.3% | |
Share capital | Rs m | 50 | 2,399 | 2.1% | |
"Free" reserves | Rs m | 2,419 | 450,245 | 0.5% | |
Net worth | Rs m | 2,469 | 452,645 | 0.5% | |
Long term debt | Rs m | 0 | 20,289 | 0.0% | |
Total assets | Rs m | 4,605 | 682,525 | 0.7% | |
Interest coverage | x | NM | 18.4 | - | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.5 | 257.7% | |
Return on assets | % | 5.6 | 6.6 | 85.5% | |
Return on equity | % | 10.5 | 9.2 | 113.4% | |
Return on capital | % | 17.7 | 11.2 | 157.9% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 74,219 | 0.4% | |
Fx outflow | Rs m | 2,015 | 27,964 | 7.2% | |
Net fx | Rs m | -1,715 | 46,255 | -3.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 65,548 | 0.1% | |
From Investments | Rs m | -94 | -25,888 | 0.4% | |
From Financial Activity | Rs m | NA | -57,151 | 0.0% | |
Net Cashflow | Rs m | -6 | -13,857 | 0.0% |
Indian Promoters | % | 0.0 | 63.7 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.3 | 5.1 | 5.8% | |
FIIs | % | 15.7 | 23.0 | 68.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 8.3 | 109.6% | |
Shareholders | 12,856 | 133,026 | 9.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare ASTRAZENECA PHARMA With: AJANTA PHARMA GLENMARK PHARMA AUROBINDO PHARMA STRIDES PHARMA SCIENCE FDC
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.
ASTRAZENECA PHARMA share price is trading down by 5% and its current market price is Rs 4,200. The BSE HEALTHCARE is down by 2.5%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 1.2%) and IPCA LABS (up 1.0%). The top losers are ASTRAZENECA PHARMA (down 5.3%) and WOCKHARDT (down 5.2%).
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More